Stay updated on Clinical Trial: INO-3112 & Durvalumab for HPV Cancers
Sign up to get notified when there's something new on the Clinical Trial: INO-3112 & Durvalumab for HPV Cancers page.

Latest updates to the Clinical Trial: INO-3112 & Durvalumab for HPV Cancers page
- Check3 days agoChange DetectedRevision: v3.3.4 replaces v3.3.3. No substantive study content or functionality changes are indicated.SummaryDifference0.0%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedAdded a dedicated Locations section and listed Texas as a location, replacing the previous Texas Locations grouping. Updated the revision to v3.3.3 and removed the HHS Vulnerability Disclosure link.SummaryDifference0.2%

- Check53 days agoChange DetectedThe page now displays Revision: v3.3.2, replacing Revision: v3.2.0.SummaryDifference0.0%

- Check60 days agoChange DetectedThe funding-status banner regarding government operations was removed; there is no change to the study details, eligibility criteria, or results sections. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check74 days agoChange DetectedThe page now shows a 'Results First Posted' date (2024-07-09) and related results reporting details for NCT03439085.SummaryDifference0.4%

- Check103 days agoChange Detected- Added a government funding lapse notice and operating-status guidance, plus a version bump to v3.2.0. - Removed the old version reference v3.1.0.SummaryDifference2%

Stay in the know with updates to Clinical Trial: INO-3112 & Durvalumab for HPV Cancers
Enter your email address, and we'll notify you when there's something new on the Clinical Trial: INO-3112 & Durvalumab for HPV Cancers page.